About

The Luminesce Alliance Functional Genomics Enabling Platform provides subsidised support services for translational research projects in paediatric precision medicine, encompassing research activity in research genomics, genomic medicine, regenerative medicine and advanced therapeutics across genetic diseases, neurodevelopmental disorders and cancers. The Luminesce Alliance Functional Genomics Enabling Platform delivers new research capacity across stem cell medicine and vectorology by taking collaboration to the next level, allowing researchers to galvanise and intensify collaboration; accelerate translation and reinforce competitive advantages. The Functional Genomics Platform is one of Luminesce Alliance’s five enabling platforms.

Expressions of Interest

The Functional Genomics Enabling Platform is open to precision medicine research teams of Luminesce Alliance partner organisations (Sydney Children’s Hospitals Network, Children’s Medical Research Institute, Children’s Cancer Institute, University of NSW, University of Sydney) requiring subsidised functional genomics research services.

The Expression of Interest (EOI) supports three key paediatric precision medicine research streams:
(1) Inherited retinal disorders and vision impairment
(2) Neurodevelopmental disorders
(3) Telomere disorders – haematological diseases and bone marrow failure
Other research in emerging disease streams where the Enabling Platform can deliver new research capacity across stem cell medicine and vectorology may also be considered.

The Functional Genomics Enabling Platform will consider the expression of interest (EOI) to access the following facilities:

• Research Genomics: biochemical genetics, proteomics, metabolomics
• Single-Cell Omics Analytics
• Stem Cell and Organoid Facility
• Genome Engineering
• Vector Engineering
• Advanced Imaging
• Functional Genomics Data Analytics

A template of the EOI is available to download here.

The EOI should address the relevance of the research project for precision medicine based on the three key paediatric precision medicine research streams outlined above and specify the subsidised support required from the Functional Genomics Enabling Platform for enhancing the delivery of the research outcome.

The EOI will be evaluated by the scientific panel of the Enabling Platform for suitability and feasibility of subsidised support. The investigator will be advised on the outcome of evaluation within 15working days after submission of the EOI.

For Successful EOI, a project proposal defining the scope of work will need to be developed by the investigator, for the Enabling Platform to formulate a plan of provision of support service regarding resource availability, timeline and costing of the service. Work will commence when the project proposal is approved by the Platform and the plan of service provision is accepted by the investigator. Services provided by the Enabling Platform are subsidised services, and some costs to researchers will be incurred.

Enquiries may be directed to: CMRI Scientific Facilities Engagement and Service Support email researchfacilities@cmri.org.au or Patrick Tam, Lead Investigator, Functional Genomics Enabling Platform email: ptam@cmri.org.au

EOIs are to be submitted via email to: researchfacilities@cmri.org.au